AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019 - ResearchAndMarkets.com

January 21, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 21, 2020--

The “Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) - Tyrosine-protein phosphatase non-receptor type 1 also known as protein-tyrosine phosphatase 1B (PTP1B) is an enzyme encoded by the PTPN1 gene. It acts as a regulator of endoplasmic reticulum unfolded protein response. It plays an important role in CKII- and p60c-src-induced signal transduction cascades. It regulates the EFNA5-EPHA3 signaling pathway which modulates cell reorganization and cell-cell repulsion. It mediates dephosphorylation of EIF2AK3/PERK, inactivating the protein kinase activity of EIF2AK3/PERK. It regulates the hepatocyte growth factor receptor signaling pathway through dephosphorylation of MET.

Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) pipeline Target constitutes close to 12 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System, Genetic Disorders, Cardiovascular, Genito Urinary System And Sex Hormones, Musculoskeletal Disorders and Oncology which include indications Type 2 Diabetes, Obesity, Diabetes, Rett Syndrome, Acute Renal Failure (ARF) (Acute Kidney Injury), Chronic Heart Failure, Duchenne Muscular Dystrophy, Metastatic Breast Cancer, Muscle Injury and Wilson Disease.

The latest report Tyrosine Protein Phosphatase Non Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Phosphatase Non Receptor Type 1 (Protein Tyrosine Phosphatase 1B or Protein Tyrosine Phosphatase Placental or PTP1B or PTPN1 or EC 3.1.3.48) targeted therapeutics development with respective active and dormant or discontinued projects.

Scope

Reasons to buy

Key Topics Covered:

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sx4f10

View source version on businesswire.com:https://www.businesswire.com/news/home/20200121005516/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH GENERAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/21/2020 05:35 AM/DISC: 01/21/2020 05:35 AM

http://www.businesswire.com/news/home/20200121005516/en